Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,397.98 -26.87 -0.16%
S&P 500 1,862.89 0.58 0.03%
NASDAQ 4,084.00 -2.23 -0.05%
Ticker Volume Price Price Delta
STOXX 50 3,155.73 16.47 0.52%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Sonova proposes Stacy Enxing Seng for election to the Board of D



Media Release

Sonova proposes Stacy Enxing Seng for election to the Board of Director

Staefa (Switzerland), 31 January 2014 - Sonova Holding AG, the world's leading
provider of hearing solutions, announces today that its Board of Directors
nominates Stacy Enxing Seng as a new board member for election at the next
Annual General Meeting in June 2014. Ms. Enxing Seng is currently serving as
President of Covidien's global Vascular Therapies business.

"We are very pleased to propose Ms. Enxing Seng as a new member to the Board
of Directors. Drawing on her impressive track record in growing startups and
leading multinational companies, she will be a very important addition to the
current Board of Directors. Ms. Enxing Seng's extensive experience in the
medtech industry and her commitment to innovation will bring most valuable
perspectives to Sonova," says Robert Spoerry, Chairman of the Board of
Directors of Sonova Holding AG.

Ms. Enxing Seng (born in 1964, US citizen) is currently responsible for
managing a global organization of approximately 4,000 employees with $1.6
billion in revenue. She joined Covidien in July 2010 through the ev3
acquisition where she was a founding member and executive officer responsible
for leading ev3's peripheral vascular division from inception to a $350
million business. Ms. Enxing Seng has held various positions of increasing
responsibility in the healthcare and medtech industry. She received a Master
of Business Administration from Harvard University and has a Bachelor of Arts
in Public Policy from Michigan State University.

"I am delighted to join the Board of Directors of Sonova," said Ms. Enxing
Seng. "I have always been passionate about the healthcare and medtech
industry, making a difference in the lives of others. I am excited to become
part of a growing company which is offering highly innovative products,
allowing people with hearing loss to live better lives."

- End -

Contacts:

Investor Relations                           Media Relations
Thomas Bernhardsgrütter                      Michael Isaac
Phone   +41 58 928 33 44                     Phone   +41 58 928 33 24
Mobile  +41 79 618 28 07                     Mobile  +41 79 420 29 56
Email   thomas.bernhardsgruetter@sonova.com  Email   michael.isaac@sonova.com
Corinne Hofmann
Phone   +41 58 928 33 22
Email   corinne.hofmann@sonova.com

Disclaimer

This Media Release contains forward-looking statements, which offer no
guarantee with regard to future performance. These statements are made on the
basis of management's views and assumptions regarding future events and
business performance at the time the statements are made. They are subject to
risks and uncertainties including, but not confined to, future global economic
conditions, exchange rates, legal provisions, market conditions, activities by
competitors and other factors outside Sonova's control. Should one or more of
these risks or uncertainties materialize or should underlying assumptions
prove incorrect, actual outcomes may vary materially from those forecasted or
expected. Each forward-looking statement speaks only as of the date of the
particular statement, and Sonova undertakes no obligation to publicly update
or revise any forward-looking statements, except as required by law.

About Sonova

Sonova Holding AG, headquartered in Staefa, Switzerland, is the leading
manufacturer of innovative hearing care solutions. The Group operates through
its core business brands Phonak, Unitron, Advanced Bionics and Connect
Hearing. Sonova offers its customers one of the most comprehensive product
portfolios in the industry - from hearing instruments to cochlear implants to
wireless communication solutions. Founded in 1947, the Group is currently
present in over 90 countries across the globe and has a workforce of over
9,000 dedicated employees. Sonova generated sales of CHF 1.8 billion in the
financial year 2012/13 and a normalized net profit of CHF 309 million. By
supporting the Hear the World Foundation, Sonova pursues its vision of a world
where everyone enjoys the delight of hearing and therefore lives a life
without limitations.

For more information please visit www.sonova.com and www.hear-the-world.com.

Sonova shares (ticker symbol:SOON, Security no: 1254978, ISIN: CH1012549785)
have been listed on the SIX Swiss Exchange since 1994. The securities of
Sonova have not been and will not be registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or under the applicable
securities laws of any state of the United States of America, and may not be
offered or sold in the United States of America except pursuant to an
exemption from the registration requirements under the U.S. Securities Act and
in compliance with applicable state securities laws, or outside the United
States of America to non-U.S. Persons in reliance on Regulation S under the
U.S. Securities Act.

Media Release (PDF)

Provider                  Channel         Contact
Tensid Ltd., Switzerland  newsbox.ch      Provider/Channel related enquiries
www.tensid.ch             www.newsbox.ch  marco@tensid.ch
                                          +41 41 763 00 50
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement